CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells

Despite improvement in treatment options for myeloma patients, including targeted immunotherapies, multiple myeloma remains a mostly incurable malignancy. High CS1 (SLAMF7) expression on myeloma cells and limited expression on normal cells makes it a promising target for CAR-T therapy. The CS1 prote...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Neal, Julie, Ritchey, Julie K., Cooper, Matthew L., Niswonger, Jessica, Sofía González, L., Street, Emily, Rettig, Michael P., Gladney, Susan W., Gehrs, Leah, Abboud, Ramzi, Prior, Julie L., Haas, Gabriel J., Jayasinghe, Reyka G., Ding, Li, Ghobadi, Armin, Vij, Ravi, DiPersio, John F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162922/
https://www.ncbi.nlm.nih.gov/pubmed/35422095
http://dx.doi.org/10.1038/s41375-022-01559-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162922/
https://www.ncbi.nlm.nih.gov/pubmed/35422095
http://dx.doi.org/10.1038/s41375-022-01559-4

Ejemplares similares